Analyst Price Targets — NXTC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 15, 2025 10:46 am | Edward Tenthoff | Piper Sandler | $15.00 | $4.76 | TheFly | NextCure price target lowered to $15 from $36 at Piper Sandler |
| June 3, 2024 8:19 am | Edward Tenthoff | Piper Sandler | $3.00 | $1.52 | StreetInsider | Piper Sandler Reiterates Overweight Rating on NextCure Inc. (NXTC) |
| November 3, 2022 9:20 pm | Edward Tenthoff | Piper Sandler | $6.00 | $2.51 | TheFly | NextCure price target lowered to $6 from $13 at Piper Sandler |
Latest News for NXTC
BELTSVILLE, Md., April 07, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced that the U.S. Food And Drug Administration (FDA) has granted Fast Track Designation for SIM0505 for the treatment of platinum-resistant ovarian cancer. SIM0505 is an…
BELTSVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd.
BELTSVILLE, Md., March 05, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported full year 2025 financial results.
BELTSVILLE, Md., Jan. 23, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today provided updates for its two antibody drug conjugate (ADC) programs and reported a preliminary year-end 2025 cash position.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NXTC.
U.S. House Trading
No House trades found for NXTC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.